nach oben

Erschienen in:

14.03.2018 | Magnetresonanztomografie | Fortbildung

Affektive Erkrankungen

Therapieprädiktion und (f)MRT-basierte Biomarker bei Depression

verfasst von: Marie Wölfer, Anna Linda Leutritz, Prof. Dr. med. Martin Walter

Erschienen in: NeuroTransmitter | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Studien der Magnetresonanztomografie (MRT) geben uns einen neuartigen Einblick in affektive Erkrankungen. Mittels Biomarkern aus der Bildgebung ist es prinzipiell möglich für depressive Patienten die Wahrscheinlichkeit für ein Therapieansprechen zu berechnen und Faktoren für eine Therapieresistenz zu detektieren. MRT-basierte Biomarker können damit entscheidend zur Entwicklung einer individuellen Therapieplanung in der Psychiatrie beitragen.

Mathers C The global burden of disease: 2004 update. World Health Organization, Place 2008 Published

Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. The American journal of psychiatry 2006 163:28–40CrossRef

Derubeis RJ, Siegle GJ, Hollon SD Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nature Reviews Neuroscience 2008 9:788–796CrossRef

Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR The STAR*D project results: A comprehensive review of findings. Current Psychiatry Reports 2007 9:449–459CrossRef

Insel TR, Cuthbert BN Brain disorders? Precisely. Science 2015 348:499–500CrossRef

Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature medicine 2017 23:28–38CrossRef

Hahn T, Nierenberg A, Whitfield-Gabrieli S Predictive analytics in mental health: applications, guidelines, challenges and perspectives. Molecular psychiatry 2016

Trusheim MR, Berndt ER, Douglas FL Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007 6:287–293CrossRef

Altevogt B, Hanson S, Davis M Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships: Workshop Summary. National Academies Press, Place 2008 Published

10.

Carroll B, Cassidy F, Naftolowitz D, Tatham N, Wilson W, Iranmanesh A et al. Pathophysiology of hypercortisolism in depression. Acta Psychiatrica Scandinavica 2007 115:90–103CrossRef

11.

Castrén E, Rantamäki T The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Developmental neurobiology 2010 70:289–297CrossRef

12.

Schmidt HD, Shelton RC, Duman RS Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011 36:2375–2394CrossRef

13.

Labermaier C, Masana M, Müller MB Biomarkers predicting antidepressant treatment response: how can we advance the field? Disease markers 2013 35:23–31CrossRef

14.

Sackeim HA, Prohovnik I, Moeller JR, Brown RP, Apter S, Prudic J et al. Regional cerebral blood flow in mood disorders. I. Comparison of major depressives and normal controls at rest. Arch Gen Psychiatry 1990 47:60–70CrossRef

15.

Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, Mcginnis S et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological psychiatry 2000 48:830–843CrossRef

16.

Pittenger C, Duman RS Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008 33:88–109CrossRef

17.

Mayberg HS Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. British medical bulletin 65.1: 193–207. 2003CrossRef

18.

Walter M, Henning A, Grimm S, Schulte RF, Beck J, Dydak U et al. The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 2009 66:478–486CrossRef

19.

Bench CJ, Frackowiak RS, Dolan RJ Changes in regional cerebral blood flow on recovery from depression. Psychological medicine 1995 25:247–261CrossRef

20.

Passero S, Nardini M, Battistini N Regional cerebral blood flow changes following chronic administration of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry 1995 19:627–636CrossRef

21.

Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997 8:1057–1061CrossRef

22.

Kennedy SH, Kr E S K, Mayberg HS, Meyers J S M et al. Changes in Regional Brain Glucose Metabolism Measured With Positron Emission Tomography After Paroxetine Treatment of Major Depression. American Journal of Psychiatry 2001 158:899–905CrossRef

23.

Li M, Demenescu LR, Colic L, Metzger CD, Heinze H-J, Steiner J et al. Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2017 42:1201–1209CrossRef

24.

Davidson RJ, Irwin W, Anderle MJ, Kalin NH The neural substrates of affective processing in depressed patients treated with venlafaxine. The American journal of psychiatry 2003 160:64–75CrossRef

25.

Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. The American journal of psychiatry 2003 160:522–532CrossRef

26.

Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA, Jr. et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009 65:289–295CrossRef

27.

Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biological psychiatry 2012 72:595–603CrossRef

28.

Wu J, Buchsbaum MS, Gillin JC, Tang C, Cadwell S, Wiegand M et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry 1999 156:1149–1158PubMed

29.

Pizzagalli DA Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2011 36:183–206CrossRef

30.

Mayberg HS Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003 65:193–207CrossRef

31.

Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of general psychiatry 2004 61:34–41CrossRef

32.

Yoshimura S, Okamoto Y, Onoda K, Matsunaga M, Okada G, Kunisato Y et al. Cognitive behavioral therapy for depression changes medial prefrontal and ventral anterior cingulate cortex activity associated with self-referential processing. Soc Cogn Affect Neurosci 2014 9:487–493CrossRef

33.

Roiser JP, Elliott R, Sahakian BJ Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 2012 37:117–136CrossRef

34.

Straub J, Plener PL, Sproeber N, Sprenger L, Koelch MG, Groen G et al. Neural correlates of successful psychotherapy of depression in adolescents. J Affect Disord 2015 183:239–246CrossRef

35.

Dichter GS, Gibbs D, Smoski MJ A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. Journal of affective disorders 2015 172:8.17CrossRef

36.

Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry 2002 51:693–707CrossRef

37.

Drevets WC Prefrontal cortical-amygdalar metabolism in major depression. Annals of the New York Academy of Sciences 1999 877:614–637CrossRef

38.

Lui S, Wu, Q., Qiu, L., Yang, X., Kuang, W., Chan, R. C., Gong, Q Resting-State Functional Connectivity in Treatment-Resistant Depression. American Journal of Psychiatry 2011:168(166), 642–648CrossRef

39.

Liao Y, Huang X, Wu Q, Yang C, Kuang W, Du M et al. Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. Journal of psychiatry & neuroscience: JPN 2013 38:49CrossRef

40.

Freo U, Ori C, Dam M, Merico A, Pizzolato G Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies. Brain research 2000 854:35–41CrossRef

41.

Duman RS Depression: a case of neuronal life and death? Biological psychiatry 2004 56:140–145CrossRef

42.

Schmaal L, Veltman DJ, Van Erp TG, Samann PG, Frodl T, Jahanshad N et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2016 21:806–812CrossRef

43.

Sheline YI, Gado MH, Kraemer HC Untreated depression and hippocampal volume loss. Am J Psychiatry 2003 160:1516–1518CrossRef

44.

Frodl T, Meisenzahl EM, Zetzsche T, Höhne T, Banac S, Schorr C et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. Journal of Clinical Psychiatry 2004

45.

Frodl T, Jäger M, Smajstrlova I, Born C, Bottlender R, Palladino T et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. Journal of psychiatry & neuroscience: JPN 2008 33:423

46.

Malykhin NV, Peter Seres Bsc M, Coupland NJ Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. Journal of psychiatry & neuroscience: JPN 2010 35:337CrossRef

47.

Fu CH, Steiner H, Costafreda SG Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiology of disease 2013 52:75–83CrossRef

48.

Lener MS, Iosifescu DV In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. Ann N Y Acad Sci 2015 1344:50–65CrossRef

49.

Rajkowska G Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000 48:766–777CrossRef

50.

Sapolsky RM Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000 57:925–935CrossRef

51.

Horn DI, Yu C, Steiner J, Buchmann J, Kaufmann J, Osoba A et al. Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Frontiers in systems neuroscience 2010 4

52.

Soriano-Mas C, Hernández-Ribas R, Pujol J, Urretavizcaya M, Deus J, Harrison BJ et al. Cross-sectional and longitudinal assessment of structural brain alterations in melancholic depression. Biological psychiatry 2011 69:318–325CrossRef

53.

Chen C-H, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biological psychiatry 2007 62:407–414CrossRef

54.

Korgaonkar MS, Rekshan W, Gordon E, Rush AJ, Williams LM, Blasey C et al. Magnetic resonance imaging measures of brain structure to predict antidepressant treatment outcome in major depressive disorder. EBioMedicine 2015 2:37–45CrossRef

55.

Crowther A, Smoski MJ, Minkel J, Moore T, Gibbs D, Petty C et al. Resting-state connectivity predictors of response to psychotherapy in major depressive disorder. Neuropsychopharmacology 2015 40:1659–1673CrossRef

56.

Mcgrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013 70:821–829CrossRef

57.

Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 2009 166:702–710CrossRef

58.

Mitterschiffthaler MT, Kumari V, Malhi GS, Brown RG, Giampietro VP, Brammer MJ et al. Neural response to pleasant stimuli in anhedonia: an fMRI study. Neuroreport 2003 14:177–182CrossRef

59.

Ten Doesschate F, Van Eijndhoven P, Tendolkar I, Van Wingen GA, Van Waarde JA Pre-treatment amygdala volume predicts electroconvulsive therapy response. Front Psychiatry 2014 5:169CrossRef

60.

Redlich R, Opel N, Grotegerd D, Dohm K, Zaremba D, Burger C et al. Prediction of Individual Response to Electroconvulsive Therapy via Machine Learning on Structural Magnetic Resonance Imaging Data. JAMA psychiatry 2016 73:557–564CrossRef

61.

Costafreda SG, Chu C, Ashburner J, Fu CH Prognostic and diagnostic potential of the structural neuroanatomy of depression. PloS one 2009 4:e6353CrossRef

62.

Gong Q, Wu Q, Scarpazza C, Lui S, Jia Z, Marquand A et al. Prognostic prediction of therapeutic response in depression using high-field MR imaging. NeuroImage 2011 55:1497–1503CrossRef

63.

Van Waarde JA, Scholte HS, Van Oudheusden LJ, Verwey B, Denys D, Van Wingen GA A functional MRI marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression. Mol Psychiatry 2015 20:609–614CrossRef

64.

Raichle ME, Macleod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL A default mode of brain function. Proc Natl Acad Sci U S A 2001 98:676–682CrossRef

65.

Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proceedings of the National Academy of Sciences of the United States of America 2005 102:9673–9678CrossRef

66.

Sheline YI, Barch DM, Price JL, Rundle MM, Vaishnavi SN, Snyder AZ et al. The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A 2009 106:1942–1947CrossRef

67.

Sheline YI, Price JL, Yan Z, Mintun MA Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proceedings of the National Academy of Sciences of the United States of America 2010 107:11020–11025CrossRef

68.

Nejad AB, Fossati P, Lemogne C Self-referential processing, rumination, and cortical midline structures in major depression. Front Hum Neurosci 2013 7:666CrossRef

69.

Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biological psychiatry 2014 76:517–526CrossRef

70.

Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. JAMA psychiatry 2015 72:603–611CrossRef

71.

Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PloS one 2012 7:e44799CrossRef

72.

Li B, Liu L, Friston KJ, Shen H, Wang L, Zeng L-L et al. A treatment-resistant default mode subnetwork in major depression. Biological psychiatry 2013 74:48–54CrossRef

73.

Andreescu C, Tudorascu DL, Butters MA, Tamburo E, Patel M, Price J et al. Resting state functional connectivity and treatment response in late-life depression. Psychiatry Research: Neuroimaging 2013 214:313–321CrossRef

74.

Alexopoulos GS, Hoptman MJ, Kanellopoulos D, Murphy CF, Lim KO, Gunning FM Functional connectivity in the cognitive control network and the default mode network in late-life depression. Journal of affective disorders 2012 139:56–65CrossRef

75.

Wang L, Hermens DF, Hickie IB, Lagopoulos J A systematic review of resting-state functional-MRI studies in major depression. J Affect Disord 2012 142:6–12CrossRef

76.

Newton-Howes G, Tyrer P, Johnson T Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006 188:13–20CrossRef

77.

Wu JT, Wu HZ, Yan CG, Chen WX, Zhang HY, He Y et al. Aging-related changes in the default mode network and its anti-correlated networks: a resting-state fMRI study. Neurosci Lett 2011 504:62–67CrossRef

78.

Song J, Desphande AS, Meier TB, Tudorascu DL, Vergun S, Nair VA et al. Age-related differences in test-retest reliability in resting-state brain functional connectivity. PLoS One 2012 7:e49847CrossRef

79.

Ritchie SJ, Cox SR, Shen X, Lombardo MV, Reus LM, Alloza C et al. Sex differences in the adult human brain: Evidence from 5,216 UK Biobank participants. bioRxiv 2017:123729

Titel: Affektive Erkrankungen
Therapieprädiktion und (f)MRT-basierte Biomarker bei Depression
verfasst von: Marie Wölfer
Anna Linda Leutritz
Prof. Dr. med. Martin Walter
Publikationsdatum: 14.03.2018
Verlag: Springer Medizin
Schlagwörter: Magnetresonanztomografie
Affektive Störungen
Affektive Störungen
EKT
Magnetresonanztomografie
Biomarker
Erschienen in: NeuroTransmitter / Ausgabe 3/2018
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI: https://doi.org/10.1007/s15016-018-6324-x

Passend zum Thema

Mittelgradige Depressionen & Johanniskraut: Das hat sich geändert

Affektive Störungen

Die Behandlungsempfehlungen bei mittelgradiger Depression wurden erneuert und der Einsatz von Johanniskraut entscheidend präzisiert – welche zwei Empfehlungen Sie aus der aktualisierten Depressions-Leitlinie jetzt kennen sollten.

3 Kernaussagen: Cochrane-Analyse untersucht Johanniskrautextrakte

Affektive Störungen

Johanniskraut gehört zu den am besten untersuchten pflanzlichen Arzneimitteln. Die Ergebnisse zur Wirksamkeit bei Depressionen wurden u. a. in einem Cochrane-Review analysiert [1]. Wie das pflanzliche Antidepressivum dabei abschnitt und welche drei Kernaussagen Sie für die Praxis kennen sollten, lesen Sie hier.

Depression behandeln. Natürlich.

Content Hub

Aktuelle Ergebnisse aus in-vitro- und in-vivo-Untersuchungen liefern detaillierte Erklärungen zum Wirkmechanismus von hochdosiertem Johanniskraut-Extrakt: Neu ist die Erkenntnis, dass der Johanniskraut-Extrakt bei chronischem Stress die deregulierte Stressantwort der überaktiven HPA-Achse sowie die Expression des Stressgens FKBP5 normalisieren kann. Mehr zum aktuellen Stand der Wissenschaft bei der Therapie von Depressionen erfahren Sie hier.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Weitere Konnektoren vom DGN und Telekom angekündigt

Betrieblich genutzten PKW steuerlich ansetzen

Erwachsenen-ADHS richtig erkennen

Wir brauchen keinen Psychiater „light“!

Änderungen im Mutterschutz — Was Praxischefs wissen müssen

Wie aus Daten Kunst wird Data Artists

Passend zum Thema

Mittelgradige Depressionen & Johanniskraut: Das hat sich geändert

3 Kernaussagen: Cochrane-Analyse untersucht Johanniskrautextrakte

Depression behandeln. Natürlich.